更年期激素治療和癡呆風險增加之間

Use of menopausal hormone therapy (MHT, also known as hormone replacement therapy, HRT) is not associated with an increased risk of developing dementia, regardless of hormone type, dose, or duration, concludes a large UK study published by The BMJ today.

英國醫(yī)學雜志今天發(fā)表的一項大型英國研究得出結(jié)論，無論激素類型、劑量或持續(xù)時間如何，使用更年期激素療法(MHT，也稱為激素替代療法，HRT)與患癡呆癥的風險增加無關(guān)。

Within the subgroup of women with a specific diagnosis for Alzheimer's disease, a slightly increased risk association was found with the use of oestrogen-progestogen treatments, but measurable only for long-term usage (5 years or more).

在被診斷為阿爾茨海默病的亞組婦女中，發(fā)現(xiàn)使用雌激素-孕激素治療的風險略有增加，但僅在長期使用(5年或更長)時可測量。

The researchers say this study "brings clarity to previously inconsistent findings and should reassure women in need of menopausal hormonal therapy."

研究人員說，這項研究“澄清了以前不一致的發(fā)現(xiàn)，應(yīng)該讓需要更年期激素治療的女性放心。”

MHT is used to relieve menopausal symptoms such as hot flushes, sleep disturbance, mood swings, memory loss, and depression. Treatments include tablets containing oestrogen only, or a combination of oestrogen and progestogen, as well as patches, gels, and creams.

MHT用于緩解更年期癥狀，如潮熱、睡眠障礙、情緒波動、記憶力喪失和抑郁。治療方法包括只含有雌激素的藥片，或雌激素和孕激素的混合物，以及貼劑、凝膠和乳霜。

Some menopausal symptoms are similar to early signs of dementia. Laboratory studies and small trials have suggested a beneficial link between oestrogen and age-related brain decline. However, the largest trial of MHT, the Women's Health Initiative Memory Study, found an increased risk of developing dementia among users of oestrogen-progestogen treatments.

一些更年期癥狀類似于癡呆癥的早期癥狀。實驗室研究和小型試驗表明，雌激素與年齡相關(guān)的大腦衰退之間存在有益的聯(lián)系。然而，MHT最大的試驗，婦女健康倡議記憶研究，發(fā)現(xiàn)雌激素-孕激素治療的使用者患癡呆癥的風險增加。

A recent large observational study in Finland flagged an increased risk of developing Alzheimer's disease among users of both oestrogen-only and oestrogen-progestogen treatments, but the study had some methodological weaknesses.

最近在芬蘭進行的一項大型觀察性研究表明，僅使用雌激素和雌激素-孕激素治療的患者患阿爾茨海默病的風險增加，但該研究在方法上存在一些缺陷。